GCP
TCON

GSA Capital Partners’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

GSA Capital Partners’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,300
Closed -$333K – 1889
2021
Q3 		$333K Buy
4,300
+2,481
+136% +$210K 0.03% 951
2021
Q2 		$236K Buy
1,819
+536
+42% +$74.1K 0.03% 1097
2021
Q1 		$211K Sell
1,283
-1,036
-45% -$199K 0.04% 873
2020
Q4 		$543K Sell
2,319
-1,765
-43% -$246K 0.09% 374
2020
Q3 		$422K Buy
+4,084
New +$219K 0.07% 496

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GSA Capital Partners's TCON Position: Q4 2021 in Review

GSA Capital Partners sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2021, closing a stake of 4,300 shares — an estimated $333K sold.

GSA Capital Partners first reported a position in TCON in Q3 2020 and held it in 5 quarters. The position peaked at $543K in Q4 2020. 35 funds tracked by Wall St. Rank hold TCON as of Q4 2021.

  • GSA Capital Partners reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 4,300 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $333K.
  • GSA Capital Partners first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • GSA Capital Partners's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $543K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.